Key result
Intravenous tenecteplase (0.25 mg/kg) administered within 4.5 hours of acute ischemic stroke onset achieved a reduction of at least 4 points on the NIHSS at 7 days in 50% of patients.
Why the study?
Tenecteplase has shown beneficial effects in recent years, prompting research into its effectiveness and side effects in acute ischemic stroke.
Does tenecteplase improve neurological deficits in patients with acute ischemic stroke?
Observational (n=36)
No
Does tenecteplase improve neurological deficits in patients with acute ischemic stroke?
Tenecteplase 0.25 mg/kg demonstrated efficacy and safety for acute ischemic stroke thrombolysis within 4.5 hours of symptom onset in an Iranian cohort.
Does not support routine tenecteplase adoption in stroke; leaves open efficacy versus standard care in trials.
Background & Objective: Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) has been considered as primary therapy in ischemic stroke patients.Alteplase is prescripted as the thrombolytic therapy for more than two decades.Tenecteplase is a new type of tPA that is reported to have beneficial effects in recent years.The present research focused on the effectiveness and the side effects of tenecteplase in the ischemic stroke. Materials & Methods:Here we administrated 0.25 mg/kg tenecteplase in 36 individuals with acute ischemic stroke in the first 4.5 hours of stroke occurrence.The NIHSS in baseline, 24 hours, 7 days after and the modified Rankin scale (mRS) at 90 days were assessed.The primary efficacy outcome was reduction of at least 4 points in the NIHSS during 7 days and the secondary efficacy outcome was defined as mRS 0 and 1 at 90 days.The safety outcome was evaluated based on the symptomatic intracranial hemorrhage (ICH) and death occurance during 90 days. Results:The mean NIHSS at baseline was 12.7±4.6,and the mean NIHSS corresponding to 24 hours after admission was 9.6±4.8.The mean 7-day NIHSS was 7.6±4.4.The primary and secondary efficacy outcomes were met in 18 (50%) and 22 (61.1 %) of the patients respectively.Symptomatic ICH was observed in one patient with lung cancer who died of respiratory failure.Conclusion: This study confirmed the efficacy and safety of tenecteplase in thrombolysis for acute ischemic stroke treatment.Tenecteplase appears to be an appropriate therapy as thrombolytic agent against ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Rafie et al. (2024) conducted an observational in Acute Ischemic Stroke (n=36). Tenecteplase was evaluated on Reduction of at least 4 points in the NIHSS during 7 days. Intravenous tenecteplase (0.25 mg/kg) administered within 4.5 hours of acute ischemic stroke onset achieved a reduction of at least 4 points on the NIHSS at 7 days in 50% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: